Canaccord Genuity 2020 Virtual U.S. Cannabis Symposium
September 30, 2020
OTCQX: MRMD
Important Disclaimer & Cautions Regarding Forward Looking Statements

This presentation does not constitute an offer to sell or a solicitation of an offer to buy securities or assets of MariMed Inc. (“MariMed” or the “Company”). All information presented herein with respect to the existing business and the historical operating results of MariMed, and estimates and projections as to future operations, are based on materials prepared by the management of the Company and involve significant elements of subjective judgment and analysis which may or may not be correct. The Company makes no representations or warranties, expressed or implied, as to the accuracy or completeness of this information.

In furnishing this information, MariMed reserves the right to amend or replace some or all of the information herein at any time and undertakes no obligation to provide the recipient with access to any additional information. Nothing contained herein is or should be relied upon as a promise or representation as to the future.

This information includes certain statements, estimates and projections provided by MariMed with respect to its anticipated future performance. Such statements, estimates and projections constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors, which may cause actual results to be materially different from those contemplated by the forward-looking statements.

The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The recipient of this information is cautioned not to place undue reliance on forward-looking statements. No representations or warranties are made as to the accuracy of such forward-looking statements or whether any of the projections included herein will be realized.
"CANNABIS HAS THE POWER TO TRANSFORM HUMAN HEALTH AND WELLNESS."

Bob Fireman  |  CEO, MariMed Inc.
<table>
<thead>
<tr>
<th>Exchange</th>
<th>OTCQX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ticker</td>
<td>MRMD</td>
</tr>
<tr>
<td>Headquarters</td>
<td>Norwood, MA</td>
</tr>
<tr>
<td>Number of Employees</td>
<td>97</td>
</tr>
<tr>
<td>Founded</td>
<td>2011</td>
</tr>
<tr>
<td>Fiscal Year 2019 Revenue</td>
<td>$16.6 Million *</td>
</tr>
<tr>
<td>Six-month 2020 Revenue</td>
<td>$17.1 Million</td>
</tr>
</tbody>
</table>

*Does not include Hemp Revenue before adjustments
About Us

Publicly traded, vertically integrated multi-state cannabis operator (MSO) whose team has developed 17 licenses across 6 states—DE, IL, MA, MD, NV, and RI.

Designed, developed and manage over 300,000 sq ft of state-of-the-art regulatory compliant cultivation, production, distribution facilities.

Portfolio of top-quality brands, in the U.S. and abroad, including our award-winning fruit chew edibles Betty’s Eddies.

On the forefront of science and education developing proprietary precision-dosed products.
Multi-State Operator

Owned By MariMed

- Massachusetts
- Illinois
- Delaware
- Maryland
- Nevada

Managed By MariMed

- Illinois
- Nevada
- Puerto Rico
- Maine
- Rhode Island

Licensed Distribution States

KEY
- Cultivation
- Production
- Dispensary
- Licensed Distribution

© MariMed Inc. 2020 All Rights Reserved.
MariMed Consolidated

Massachusetts

- Consolidated ARL Healthcare effective December 2018
- Approved for medical program (cultivation, distribution, dispensary) in December 2019
- Opened Middleboro, MA retail store in December 2019
- First harvest February 2020, now ramping towards approx. 1,000 lbs a month.
- Approved for adult use (cultivation, distribution, dispensary) program in September 2020

Illinois

- Consolidated KPG Anna and KPG Harrisburg, medical dispensaries October 2019
- State approved KPG’s to open as both Medical and Adult-use January 2020, plus the rights to 2 additional Adult use locations
- Revenues increased 3X compared to prior year
- Third Adult-use dispensary in Mt Vernon opened in September 2020 and 4th planned for 2021
MariMed Managed Facilities

**Delaware**
- First State Compassion Center 2 of 5 licenses in the state
- 11,000 sq ft of Canopy, expanding to add 20,000 sq ft
- Revenues increased 22%+ 2018-2019
- Continued grow through expansion

**Maryland**
- Kind Therapeutics USA licensed for Grow and Processing, pre-approval for Dispensary
- 14,000 sq ft of canopy, expansion to 50,400 sq ft
- Revenues more than double previous year
- Under contract to purchase 100% equity of licensee

**Nevada**
- The Harvest Foundation, Grow license
- Applied for transfer in 2019, awaiting approval
Betty’s Eddies medicated chews are handcrafted with the finest all-natural ingredients for the best experience. Our medicated chews are lactose free, gluten free and naturally preservative free.

We’ve fused science with sanity to create convenient, delicious products that deliver a dependable dose of peace with flexible, low dose options.

Made with 3 varieties of locally grown peppers, cilantro, oregano, garlic, Cabo Rojo salt and full spectrum cannabis extract, you’ll want to put it on everything.

We select only the best strains and cultivars that perfectly embody the rich heritage of where they are grown.

Bourne Baking Company reinvents classic desserts with premium quality cannabis for a sweet treat that will leave you craving more.


Healer’s mission is to empower people to live life to its fullest in great health. We achieve this through education, advocacy, and research.

The highest standard didn't exist. So we created it.
MariMed, Inc. Brand Highlights

• 2019 Leaflink Winner - Best Selling Medical Product
  • Proprietary recipe
  • Market leader in MA, MD, RI
  • License roll-out to multiple legal cannabis states

• Launching soon.. Elderbetty’s infused fruit chews providing immunity support with Zinc, Vitamins C & D

• Top selling flower brand in MD and MA
  • Popular genetics

• Launching soon.. Pre-Rolls, Live Rosin, RSO Syringe, RSO Capsules
<table>
<thead>
<tr>
<th>Brand</th>
<th>Highlights</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tropizen</td>
<td>• Hot sauce from Puerto Rico infused with cannabis</td>
</tr>
<tr>
<td></td>
<td>• Launched in MA</td>
</tr>
<tr>
<td>BB Co.</td>
<td>• Launched in MA</td>
</tr>
<tr>
<td>Kalm Fusion</td>
<td>• Chewable tablets and drink mix</td>
</tr>
<tr>
<td></td>
<td>• Market leader in DE, MA &amp; MD</td>
</tr>
<tr>
<td>Florraine</td>
<td>• CBD derived from hemp</td>
</tr>
</tbody>
</table>
MariMed Hemp

Hemp CBD now legal in most jurisdictions in North America and Europe

The U.S. hemp market generated $1.1 Billion in revenues in 2018, estimated to more than double by 2022 to $2.6 Billion, according to New Frontier Data

MariMed Hemp Inc. was formed to enter the hemp market, distributing CBD products, hemp seeds and genetics

- U.S.-registered company
- Focused on the development, production and sale of the highest quality hemp-based health and wellness products in the U.S. and E.U.

Well positioned for incremental revenue growth with hemp-based CBD products

© MariMed Inc. 2020 All Rights Reserved.

CONFIDENTIAL - 12
Science, Education and Community Support

Backed by science. Across the value chain. Education to make informed healthy choices. Support the health and safety of our communities.

FOR CONSUMERS

Certificates of Analysis
3rd party verification of product available via QR code to consumers.

Use and Dosing Suggestions
Recommendations from MariMed Hemp innovation team.

FOR DISTRIBUTORS & RETAILERS

Digital Sprout Displays
CBD/Hemp education for consumers preference/needs.

Live Education
Dedicated HempEngine and MariMed Hemp Sales teams in the field.

Distributor and Retail Programs
Training, presentations, collateral, and live support for representatives and distributors.

Community Support
Donations to improve the health and safety of the communities we serve.

FOR THE MARKET

Scientific Advisory Board (SAB)
Top researchers and thought-leaders serve on MariMed Inc.’s SAB.

Research Agendas
Advance ongoing scientific research on new indications, improving trial data and broadening adoption.

Product Innovation
Led by MariMed Inc. Chief Innovation Officer, new products and modalities brought to market to our channels first.

Drive Field Advancement
Sponsor, host and support medical and CBD events globally.

© MariMed Inc. 2020 All Rights Reserved.
Current Strategy and Growth Drivers

1. CONSOLIDATION & EXPANSION OF FOOTPRINT
   Consolidate existing client operations into MariMed Inc., while expanding into new markets

2. GROW BRAND PORTFOLIO AND LICENSING REVENUE
   Continue to expand portfolio of leading brands in THC and CBD

3. INCREASE REVENUES FROM HEMP-DERIVED CBD MARKET
   Expand presence in emerging hemp CBD industry
MariMed Consolidation Plan

Background:

- MariMed historically derived revenue from consulting fees, management fees, rental income and licensing fees without “touching the plant” or owning cannabis licensed businesses.
- Real estate, equipment and assets of the licensed businesses were owned by MariMed and leased to licensed cannabis businesses (MA, IL, DE, NV and MD).
- The consolidation plan is to acquire the licensed cannabis businesses to be a fully integrated seed-to-sale multi-state operator (MSO).
- Once completed, MariMed’ Inc.’s revenue (excluding hemp) would be approximately $100 - 200 million.

Status:

- Completed: Massachusetts, Illinois
- In-Process: Maryland, Nevada, Delaware, Rhode Island
Consistent Financial Growth

Consistent growth while establishing a national advisory business (Excludes Hemp)

**Total revenues*, MariMed Inc. ($USD Million)**

<table>
<thead>
<tr>
<th>Year</th>
<th>Total Revenues</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>$1.3</td>
</tr>
<tr>
<td>2016</td>
<td>$3.6</td>
</tr>
<tr>
<td>2017</td>
<td>$6.1</td>
</tr>
<tr>
<td>2018</td>
<td>$11.9</td>
</tr>
<tr>
<td>2019</td>
<td>$16.6</td>
</tr>
</tbody>
</table>

**Total assets, MariMed Inc. ($USD Million)**

<table>
<thead>
<tr>
<th>Year</th>
<th>Total Assets</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>$3.7</td>
</tr>
<tr>
<td>2016</td>
<td>$8.6</td>
</tr>
<tr>
<td>2017</td>
<td>$31.2</td>
</tr>
<tr>
<td>2018</td>
<td>$53.0</td>
</tr>
<tr>
<td>2019</td>
<td>$61.6</td>
</tr>
</tbody>
</table>

*Note: Includes revenues from core business only. Assets exclude GenCanna investment
Year over Year 6 Month YTD Growth

Revenue CAGR 50.66%
Gross Profit CAGR 50.92%

*Note: Includes revenues from core business only

© MariMed Inc. 2020 All Rights Reserved.
## Comparative Valuation – Public Peers

<table>
<thead>
<tr>
<th>Peers</th>
<th>Ticker Symbol</th>
<th>Share Price (*)</th>
<th>Enterprise Value (*) (Millions)</th>
<th>EV/Revenue (*)</th>
<th>EV/EBITDA (*)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AYR</td>
<td>AYR</td>
<td>$17.00</td>
<td>$815M</td>
<td>2.4X</td>
<td>5.5X</td>
</tr>
<tr>
<td>Vireo</td>
<td>VREO</td>
<td>$1.07</td>
<td>$221M</td>
<td>2.0X</td>
<td>12.2X</td>
</tr>
<tr>
<td>Harvest</td>
<td>HARV</td>
<td>$1.65</td>
<td>$1,064M</td>
<td>2.4X</td>
<td>12.3X</td>
</tr>
<tr>
<td>Acreage</td>
<td>ACRG</td>
<td>$3.75</td>
<td>$619M</td>
<td>1.7X</td>
<td>15.1X</td>
</tr>
<tr>
<td><strong>Peer Average</strong></td>
<td></td>
<td>$5.87</td>
<td>$680M</td>
<td>2.2X</td>
<td>10.9X</td>
</tr>
</tbody>
</table>

** MariMed Inc. 2020 All Rights Reserved.**

<table>
<thead>
<tr>
<th></th>
<th>Ticker Symbol</th>
<th>Share Price (*)</th>
<th>Enterprise Value (*) (Millions)</th>
<th>EV/Revenue (*)</th>
<th>EV/EBITDA (*)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRMD @ Current</td>
<td></td>
<td>$0.16 US</td>
<td>$81M US</td>
<td>1.4X</td>
<td>4.0X</td>
</tr>
<tr>
<td>MRMD @ Peer Avg. **</td>
<td></td>
<td>$1.77 US</td>
<td>$517M US</td>
<td>2.2X</td>
<td>10.9X</td>
</tr>
</tbody>
</table>

* All dollar amounts in CAD $, except MariMed which is US $; Peer multiples based on Beacon Securities September 2020 report for 2021 estimates

** MariMed forecast revenue and EBITDA reflect a full year of production and sales for Massachusetts operations
### Investment Summary

<table>
<thead>
<tr>
<th>Growing Platform</th>
<th>Diverse Capabilities in Licensing and Branding</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Consolidation of operations currently under management will result in a six-state MSO once completed with estimated revenues between $100 - $200 Million.</td>
<td>• Developer of top-quality cannabis strains and products.</td>
</tr>
<tr>
<td>• Underlying operations are profitable today which will be reflected in MariMed's reported results once completed.</td>
<td>• Building licensing and distribution networks in other non-MariMed states through strategic partners.</td>
</tr>
<tr>
<td>• Proven track record of designing, developing and managing scaled cannabis facilities. A best practices approach used across all operations.</td>
<td>• Precision-dosed for consistent experience including new modalities like sublingual and ingestible.</td>
</tr>
<tr>
<td></td>
<td>• Product Innovation - new products backed by science and educations to help consumers make informed healthy choices.</td>
</tr>
</tbody>
</table>
THANK YOU

Company Contact:
Jon Levine, CFO
MariMed Inc.
Tel (781) 559-8713

Investor Contact:
KCSA Strategic Communications
MRMD@KCSA.COM